Our fully automatic chemiluminescent TDM technology is based on the use of self-developed monoclonal antibodies and the directional coupling of specific modified small molecule directional couple recognition technology, which can specifically recognize small molecule drugs and has high detection sensitivity. For example, Tacrolimus, the first-line drug to prevent rejection after liver and kidney transplantation, has achieved good therapeutic effects in clinical practice. However, due to the narrow therapeutic window and the large individual differences in pharmacokinetics, bioavailability, sensitivity, and tolerance. Different patients will have different blood drug concentrations when given the same dose of Tacrolimus. When the concentration is too low, the treatment is ineffective, but when the concentration is too high, Tacrolimus can easily elicit toxic side effects. Compared to our TDM technology, traditional monitoring methods have complicated operation, high cost, long detection time, few detected items, and the clinical results cannot be timely and effectively reported, Diagreat TDM one-stop chemiluminescence solution can realize one step report output, fully automated high-speed detection, stable and reliable results, and results can be output within minutes, which will be of great help especially for the Emergency Department. The detection equipment is small, performs up to 200 tests per hour, and is simple to maintain. It is suitable for laboratory/pharmaceutical departments of hospitals, etc., and can meet their high-precision and large-sample testing requirements.